Expres 5 mg (Tablet)

Unit Price: ৳ 7.00 (3 x 10: ৳ 210.00)

Strip Price: ৳ 70.00

Medicine Details

Orally administered
Selective serotonin reuptake inhibitor (SSRI)
Pure S-enantiomer of the racemic bicyclic phthalate derivative citalopram
At least 100 fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake
No or very low affinity for serotonergic or other receptors including alpha- and beta-adrenergic, dopamine, histamine, muscarinic, and benzodiazepine receptors

SSRI or related antidepressants should not be started until 2 weeks after stopping an MAOI
Conversely, an MAOI should not be started until at least a week after an SSRI or related antidepressant has been stopped (2 weeks in the case of paroxetine and sertraline, at least 5 weeks in the case of fluoxetine)

Contraindicated in patients with known hypersensitivity to Escitalopram or Citalopram or any of the inactive ingredients of the drug product
Concomitant use of escitalopram in patients taking monoamine oxidase/pimozide is contraindicated

Less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants
Include gastrointestinal effects, anorexia with weight loss or increased appetite and weight gain, hypersensitivity reactions, dry mouth, nervousness, anxiety, headache, insomnia, tremor, dizziness, asthenia, hallucinations, drowsiness, convulsions, galactorrhoea, sexual dysfunction, urinary retention, sweating, hypomania or mania, movement disorders and dyskinesias, visual disturbances

Consideration of potential risks and benefits of treatment during the third trimester
Excreted in human breast milk
Decision on nursing or Escitalopram therapy should take into account the risk of citalopram exposure for the infant and the benefits of Escitalopram treatment for the mother

Use with caution in patients with epilepsy, history of mania, cardiac disease, diabetes mellitus, angle-closure glaucoma, concomitant use of drugs that increase risk of bleeding, history of bleeding disorders, hepatic and renal impairment

Initial dosage is 5 mg once daily for elderly patients (>65 years of age)
Not recommended for children and adolescents (<18 years)
Dosage adjustment not necessary in patients with mild or moderate renal impairment
Caution is advised in patients with severely reduced renal function (<30 ml/min)
Initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment
Caution and extra careful dose titration is advised in patients with severely reduced hepatic function
For poor metabolizers of CYP2C19, an initial dose of 5 mg daily during the first two weeks of treatment is recommended
Abrupt discontinuation should be avoided

Symptoms include those related to the central nervous system, gastrointestinal system, cardiovascular system, and electrolyte/fluid balance conditions
No specific antidote
General symptomatic supportive measures recommended